On November 22, 2018, the European Commission approved voretigene neparvovec, making it the first gene therapy targeting a genetic disease to receive approval in both the US and EU.39–40

This approval followed the issuance of a positive opinion recommending approval of voretigene neparvovec from the Committee for Medicinal Products for Human Use (CHMP) in September 2018.41